30th Sep 2013 16:54
Clinigen Group plc
Annual Report and Accounts
Burton-on-Trent, UK - 30 September 2013 - Clinigen Group plc (AIM: CLIN, the "Company"), the global specialty pharmaceuticals and services company announces that its annual report and accounts for the year ended 30 June 2013 is available to view on the Company's website at www.clinigengroup.com.
Copies of the Annual Report and Accounts will be posted to shareholders on 7 October 2013.
- Ends -
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Peter George, Group Chief Executive Officer | |
Robin Sibson, Group Chief Financial Officer | |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) | |
James Black/Tom Ballard (Corporate Broking) | |
Peel Hunt LLP - Joint Broker | Tel: +44 (0) 20 7418 8900 |
James Steel / Dr Vijay Barathan / Jock Maxwell Macdonald | |
College Hill | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/ Claire Dickinson | Email: [email protected] |
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. Listed at The London Stock Exchange AIM, the Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of programs, providing global access for patients and their clinicians to drugs not available in their markets. For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L